Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com11-13

Cash and Cash Equivalents: $19.6 million as of September 30, 2024. Net Cash Used in Operating Activities: $19.1 million for the nine months ended September 30, 2024, compared to $22.3 million for the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483237630?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DOtY0OR6nRiB8AALujIEVg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0d08ad631036ab92845f79cde1eb970c","is_english":true,"pubTime":"2024-11-13 15:08","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483237630","market":"us","top_or_hot":-1,"title":"Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...","media":"GuruFocus.com","content":"<div>\n<p>Cash and Cash Equivalents: $19.6 million as of September 30, 2024.\nNet Cash Used in Operating Activities: $19.1 million for the nine months ended September 30, 2024, compared to $22.3 million for the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q3-070820936.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 15:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q3-070820936.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cash and Cash Equivalents: $19.6 million as of September 30, 2024.\nNet Cash Used in Operating Activities: $19.1 million for the nine months ended September 30, 2024, compared to $22.3 million for the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q3-070820936.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONCY","symbol_name":"Oncolytics Biotech Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-inc-oncy-q3-070820936.html","article_id":"2483237630","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DOtY0OR6nRiB8AALujIEVg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/0d08ad631036ab92845f79cde1eb970c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483237630","pubTimestamp":1731481700,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Cash and Cash Equivalents: $19.6 million as of September 30, 2024.Net Cash Used in Operating Activities: $19.1 million for the nine months ended September 30, 2024, compared to $22.3 million for the same period in 2023.General and Administrative Expenses: $3.1 million for Q3 2024, down from $5.2 million in Q3 2023.Research and Development Expenses: $6.8 million for Q3 2024, up from $5.8 million in Q3 2023.Net Loss: $9.5 million for Q3 2024, compared to $9.9 million for Q3 2023.Basic and Diluted Loss Per Share: 12 in Q3 2024, compared to 14 in Q3 2023.GuruFocus has detected 2 Warning Signs with ONCY.For the complete transcript of the earnings call, please refer to the full earnings call transcript.Oncolytics Biotech Inc  reported promising final data from the Bracelet One breast cancer study, showing substantial improvements in progression-free survival and overall survival when combining their therapeutic agent with paclitaxel.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ONCY":"Oncolytics Biotech Inc"},"translate_title":"Oncolytics Biotech Inc(ONCY)2024年第三季度收益看涨期权亮点：战略进展和……","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCY":1},"content_text":"Cash and Cash Equivalents: $19.6 million as of September 30, 2024.\nNet Cash Used in Operating Activities: $19.1 million for the nine months ended September 30, 2024, compared to $22.3 million for the same period in 2023.\nGeneral and Administrative Expenses: $3.1 million for Q3 2024, down from $5.2 million in Q3 2023.\nResearch and Development Expenses: $6.8 million for Q3 2024, up from $5.8 million in Q3 2023.\nNet Loss: $9.5 million for Q3 2024, compared to $9.9 million for Q3 2023.\nBasic and Diluted Loss Per Share: 12 in Q3 2024, compared to 14 in Q3 2023.\n\n\nWarning! GuruFocus has detected 2 Warning Signs with ONCY.\n\nRelease Date: November 12, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nOncolytics Biotech Inc (NASDAQ:ONCY) reported promising final data from the Bracelet One breast cancer study, showing substantial improvements in progression-free survival and overall survival when combining their therapeutic agent with paclitaxel.\nThe company is planning a registration-enabling Phase II study for HR-positive, HER2-negative metastatic breast cancer, aiming for accelerated approval based on positive clinical benefits observed.\nOncolytics Biotech Inc (NASDAQ:ONCY) is advancing its gastrointestinal cancer program, with promising efficacy signals in pancreatic cancer, supported by collaborations with GCAR and a $5 million grant from the Pancreatic Cancer Action Network.\nThe company has ongoing collaborations with major pharmaceutical companies like Roche and Pfizer, indicating strong industry interest and potential for strategic partnerships.\nFinancially, Oncolytics Biotech Inc (NASDAQ:ONCY) has managed to decrease its net cash used in operating activities compared to the previous year, reflecting efficient cash management as they ramp up efforts for registration.\n\n Negative Points \n\nThe company faces uncertainties and risks related to the execution of their clinical trials and the potential for delays in achieving regulatory approvals.\nOncolytics Biotech Inc (NASDAQ:ONCY) reported a net loss of $9.5 million for the third quarter of 2024, indicating ongoing financial challenges.\nThere is no guarantee of regulatory approval, as the FDA requires compelling data, and the company acknowledges that the FDA will not commit to approval before seeing final results.\nThe company is still in the early stages of engaging potential partners for their breast cancer program, with significant outreach efforts planned for the future.\nEnrollment timelines for their pancreatic cancer trial remain uncertain, as they need to finalize the protocol and seek FDA guidance, which could impact the speed of trial progression.\n\n Q & A Highlights \nQ: Can you provide details on the upcoming San Antonio breast cancer update? A: Thomas Heineman, Chief Medical Officer, stated that the data presented in the call are the final results. Due to timing, there will be no further updates at the San Antonio meeting.\nQ: Could you elaborate on the potential for accelerated approval in your breast cancer registration enabling study? A: Thomas Heineman explained that the study is designed to provide a clinically meaningful benefit. If results are comparable to the Bracelet study, it could lead to accelerated approval. The study aims to meet FDA criteria for clinical benefit, statistical significance, and safety.\nQ: How quickly do you expect to complete patient enrollment for the first-line PDAC trial? A: Thomas Heineman mentioned that once the protocol is finalized and discussed with the FDA, they expect efficient enrollment due to the commonality of the cancer and the involvement of high-potential recruiting sites.\nQ: Can you describe your partnering and business development approach following the metastatic breast cancer data? A: Christophe Degois, Vice President of Business Development, noted that they are preparing for a large outreach to potential partners, including big pharma and regional companies, to accelerate drug development and prepare for market launch.\nQ: What pricing assumptions are you using for market sizing? A: Christophe Degois stated they are using pricing similar to Enhertu, with a slight premium, considering the post-Enhertu positioning for most patients. Pricing varies between the US and international markets.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483237630"}